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Abstract 
A simple, specific and precise reverse phase high performance liquid chromatographic method was 
developed and validated for simultaneous estimation of Lamivudine and Tenofovir disproxil fumarate in tablets. 
Quantification was achieved by using a reverse-phase C18 column (Inertsil ODS 3V, 250 mm x 4.6 mm; 5µ) at 
31
o
C. The mobile phase consisted of a mixture of phosphate buffer and acetonitrile in the ratio of 55:45 v/v at a 
flow rate of 1.2 mL/min. The retention times of Lamivudine and Tenofovir disproxil fumarate were found to be 
2.430 min and 4.550 min respectively. The developed method was validated as per ICH Guidelines for linearity, 
accuracy, precision, detection limit, quantification limit, ruggedness, robustness, specificity and system 
suitability. The percentage recoveries for both of the drugs from their tablets were found to be 98.48 % and 
98.64 % respectively. The method may successfully be employed for the simultaneous determination of 
Lamivudine and Tenofovir disproxil fumarate in pharmaceutical tablet dosage forms. 
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1. Introduction 
Lamivudine[1]-[3] is potent nucleoside 
analogue reverse transcriptase inhibitor, chemically 
[4-amino-1-[(2R, 5S)-2- (hydroxymethyl)-1,3-
oxathiolan-5-yl]-1,2- dihydropyrimidin-2-one]  [Fig. 
1]. The drug is soluble in water and sparingly soluble 
in methanol. It can  inhibit  both  types  (I  and  II)  of  
HIV  reverse  transcriptase  of  Hepatitis B. This 
nucleoside analogue is incorporated into viral DNA 
by HIV reverse transcriptase and HBV polymerase, 
resulting in DNA chain termination.  
Tenofovir[4]-[9] is 9-[(R)- 2[[(isopropoxcarbonyl)- 
oxy] methoxy ]phosphinyl] methoxy] propyl]  
adenine  fumarate [Fig. 2]. The drug is soluble in 
water and methanol.  Tenofovir  is  a  nucleotide 
analogue  reverse  transcriptase  inhibitor,  which  
block  reverse  transcriptase,  an  enzyme  useful   in  
viral production.It is used in the treatment of HIV 
and Chronic Hepatitis B. The structure of a) 
Lamivudine and b) Tenofovir disproxil fumarate are 
shown in figure 1.  
Figure 1: Structure of a) Lamivudine and b) 
Tenofovir disproxil fumarate. 
 
(a) 
 
(b) 
 
The literature survey revealed that very few 
RP-HPLC[1]-[17]
 
and
 
spectroscopic[18] methods 
were reported for the simultaneous estimation of 
Lamivudine and Tenofovir disproxil fumarate in 
formulations. The authors now propose a new 
validated, sensitive and reproducible HPLC method 
for simultaneous determination of Lamivudine and 
Tenofovir disproxil fumarate. The applicability of 
this method in determining the drugs in commercial 
dosage forms were also studied. 
 
2. Experimental 
2.1 Materials 
Standard Tenofovir disproxil fumarate and 
Lamivudine were obtained from SD-fine chemicals, 
Maharashtra. Market formulation TENVIR-L was 
purchased from Aurobindo pharmacy Ltd, 
Hyderabad. Each tablet contains 300 mg of 
Lamivudine and 245mg of Tenofovir disproxil 
fumarate. Other materials required were HPLC grade 
water, phosphate buffer, acetonitrile HPLC grade 
(Finar chemicals Limited. Ahmadabad). 
2.2 Instrumentation  
A Shimadzu LC 20-AT VP high 
performance liquid chromatographic instrument with 
spin chrome software and an inertsil ODS (250 mm x 
4.6 mm; 5µ) column was used for separation. The 
detection was done using an UV – VIS SPD 20A 
Detector. 
2.3 Optimized Chromatographic Conditions 
An inertsil ODS, C18 (250 mm x 4.6 mm; 5 
µ) column was used for the analytical separation. The 
mobile phase consisted of mobile phase A: phosphate 
buffer (20 mM) and mobile phase B: acetonitrile in 
the ratio of 55:45 v/v (Ph3.5) with isocratic elution 
program. The flow rate was adjusted to 1.2 mL/min, 
the injection volume was set at 20 μL with a 
detection wavelength of 264 nm. The separation of 
Lamivudine and Tenofovir disproxil fumarate under 
optimised conditions is shown in figure 2. 
 
 
 
Research Article                                                                            B. Honey Diana et al /2015 
 
                                                           11 
 
Fig 2: Typical HPLC Chromatogram corresponding to mixed standard solution of 
Lamivudine and Tenofovir disproxil fumarate 
 
2.4 Preparation of Standard solutions: 
2.4.1 Lamivudine stock solution 
Lamivudine (60 mg) was accurately 
weighed and 50mL of diluent is added, allowed to 
sonication for 15 min. Then volume was made upto 
the mark with mobile phase in a 50 mL standard flask 
to get a concentration of 1200 μg/mL solution. 20 μl 
of this solution was injected and the chromatogram 
was recorded. 
2.4.2 Tenofovir stock solution 
Tenofovir (49 mg) was weighed precisely 
and 50mL of diluent is added, allowed to sonication 
for 15 min. Then volume was made upto the mark 
with sufficient volume of mobile phase in a 50 mL 
standard flask to get a concentration of 980 μg/mL 
solution. 20 μl of this solution was injected and the 
chromatogram was recorded. 
2.4.3 Preparation of mixed standard stock solution 
Lamivudine (60 mg) and Tenofovir (49 mg) 
were weighed precisely into a 50 mL volumetric 
flask and dissolved with sufficient mobile phase then 
sonicated for 15 min and the volume was made up 
with the same.  
2.5 Preparation of mixed sample solution  
Lamivudine and Tenofovir (10 tablets) were 
weighed accurately and crushed to fine powder. Each 
tablet contains 300 mg and 245 mg. The quantity of 
powder equivalent to 60 mg Lamivudine was 
weighed and dissolved by using sufficient amount of 
mobile phase in a 50 mL volumetric flask and the 
volume was made up to give a concentration 1200 
μg/mL of Lamivudine and  980 μg/mL of Tenofovir. 
The solution was filtered through 0.45 μ nylon 
membrane filter paper. Then the resulting solution 
was suitably diluted to get the working 
concentrations. 20 μl of one of this solution was 
injected and the chromatogram recorded. The amount 
of Lamivudine and Tenofovir present in each tablet 
formulation was calculated by comparing the peak 
area of the standard.  
The amount of drug in each tablet was 
calculated separately using the given formula: 
% 𝐀𝐬𝐬𝐚𝐲 =
𝐒𝐚𝐦𝐩𝐥𝐞 𝐀𝐯𝐠.𝐩𝐞𝐚𝐤 𝐚𝐫𝐞𝐚
𝐒𝐭𝐚𝐧𝐝𝐚𝐫𝐝 𝐀𝐯𝐠.𝐩𝐞𝐚𝐤 𝐚𝐫𝐞𝐚
×
𝐖𝐭.𝐨𝐟 𝐝𝐫𝐮𝐠  𝐦𝐠 
𝐝𝐢𝐥𝐮𝐭𝐢𝐨𝐧 𝐨𝐟 𝐬𝐭𝐚𝐧𝐝𝐚𝐫𝐝
×
𝐝𝐢𝐥𝐮𝐭𝐢𝐨𝐧 𝐨𝐟 𝐭𝐚𝐛𝐥𝐞𝐭 𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧
𝐰𝐭.𝐨𝐟 𝐒𝐚𝐦𝐩𝐥𝐞
×
% 𝐏𝐮𝐫𝐢𝐭𝐲
𝟏𝟎𝟎
×
𝐀𝐯𝐠.𝐰𝐭
𝐋𝐚𝐛𝐥𝐞 𝐂𝐥𝐚𝐢𝐦
× 𝟏𝟎𝟎  
2.6 System suitability parameters 
Five replicates of working mixed standard 
solution were injected and the parameters like 
theoretical plate number (N), tailing factor (K) and 
resolution are
 
calculated to check the system 
suitability. The results are presented in Table1. 
Table 1: System suitability test results 
Sr. 
No 
Parameters Lamivudine Tenofovir 
1 
Peak area 
(mV*min) 
4590.601 2252.278 
2 
No. of theoretical 
plates 
4278 3675 
3 
Retention time 
(min) 
2.430 4.550 
4 Asymmetry 1.370 1.892 
5 Resolution 7.411 
 
3. Results and Discussion 
            The chromatographic conditions were 
optimised to develop RP-HPLC method for 
simultaneous determination of Lamivudine and 
Tenofovir Disproxil Fumarate with adequate 
resolution and rapid analysis time. 
3.1 Method Validation 
   The analytical method was developed and 
validated according to ICH guidelines. Analytical 
variable parameters such as linearity, precision, 
accuracy, specificity and system suitability were 
tested using the optimized chromatographic 
conditions and instruments. 
3.1.1 Linearity 
Mixed standard stock solution was suitably 
diluted with the mobile phase to obtain the 
concentration of 72, 96, 120, 144 and 168 μg/mL of 
Lamivudine & 58.8, 78.4, 98.0, 117.6 and 137.2 
μg/mL of Tenofovir disproxil fumarate. The solution 
was filtered through 0.45 μ nylon membrane filter 
paper and 20 μl of each was injected and the 
chromatogram was recorded. Peak areas were plotted 
against concentrations and their correlation 
coefficient (R
2
) was calculated from the graph. The 
results are exhibited in Table 2. 
Table 2: Linearity study data for Lamivudine and 
Tenofovir 
Sr. No Drugs Slope Intercept 
Correlation 
coefficient 
1 Lamivudine 29.71 1067 0.995 
2 Tenofovir 18.01 487.2 0.998 
3.1.2 Accuracy  
Mixed sample solution was taken in 3 
different volumetric flasks and suitably diluted with 
mobile phase to obtain concentration of 96, 120, 144 
μg/mL of Lamivudine & 78.4, 98.0, 117.6 μg/mL of 
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Tenofovir Disproxil Fumarate  that gives 80 %, 100 
% and 120 % of the analytical method target 
concentrations. To that a known amount of standard 
Lamivudine and Tenofovir Disproxil Fumarate was 
added. The corresponding peak areas and % recovery 
were measured. The results are presented in Table 3. 
 
Table 3: Recovery study data for Lamivudine and 
Tenofovir 
Sr. No Drug %Recovery %RSD 
1 Lamivudine 98.48 0.0064 
2 Tenofovir 98.64 0.017 
 
3.1.3 Precision 
System Precision: System precision was established 
by injecting three replicate preparations of the 
standard drug solution of Lamivudine and Tenofovir 
Disproxil Fumarate. The corresponding peak areas 
and retention times were measured and % RSD 
calculated as presented in Table 4. 
Method Precision: The method precision study was 
performed for three replicate sample preparations of 
marketed formulation containing Lamivudine and 
Tenofovir Disproxil Fumarate. The corresponding 
peak areas were measured and % RSD calculated as 
exhibited in Table 4. 
 
Table 4: Precision study data for Lamivudine and Tenofovir Disproxil Fumarate 
Sr. No 
Wt. of Sample 
(mg) 
Peak area of Standard Peak area of Sample %Label claim 
Lamivudine Tenofovir LAM TDF LAM TDF 
1 208.80   4266.586 2067.055 99.34 100.27 
2 208.95 4294.931 2061.368 4265.463 2066.072 99.31 100.22 
3 208.84   4266.391 2067.921 99.33 100.31 
Mean 99.32667 100.266 
S.D 0.015275 0.04502 
%RSD 0.0153 0.044 
 
3.1.4 Specificity 
The specificity was determined to check 
whether there is any interference due to presence of 
excipients, impurities or other components with the 
retention time of analytical peaks which may affect 
the specificity of the analytical method. The HPLC 
chromatograms were recorded for the drug-matrix 
(mixture of the drug and excipient) which showed 
almost no interfering peaks within retention time 
ranges. 
3.1.5 Robustness 
Robustness of the developed analytical 
method was tested by evaluating the affect of small 
variations in analytical method parameters such as 
change in flow rate of 1.2mL/min by ±0.2 mL/min 
and change in wavelength of 264 nm by ±2 nm. The 
results are exhibited in Table 5. 
 
Table 5: Robustness study data for LAM and TDF 
System suitability 
Parameters 
% RSD of peak area 
response   (n=3) 
Mean tailing factor                        
(n=3) 
Mean retention time in 
min. (n=3) 
Variations LAM TDF LAM TDF LAM TDF 
Change in 
Flow rate 
(mL/min) 
+0.2 0.003 0.006 2.910 5.439 1.595 1.775 
0 0.87 0.52 1.370 1.892 2.430 4.550 
-0.2 0.002 0.004 2.129 3.811 1.260 1.802 
Change in 
Wavelength 
(nm) 
+2 0.017 0.004 2.406 4.617 1.541 1.631 
0 0.87 0.52 1.370 1.892 2.430 4.550 
-2 0.005 0.001 2.467 4.568 1.601 1.797 
 
3.2 Application of the method to commercial 
formulation 
  Twenty micro litres of each of the standard 
and sample solutions were injected separately. The 
chromatograms were recorded and the corresponding 
peak areas were measured. The procedure was 
repeated three times, individually weighing the tablet 
powder each time. The peak areas obtained for 
standard and sample were used to calculate the 
amount of each drug in the tablet formulation. The 
results obtained are shown in table 6. The 
chromatogram showing separation of Lamivudine 
and Tenofovir in tablet formulation is shown in 
figure 3. 
 
Table 6: Results for tablet formulation study 
Sr. 
No 
Wt. of std. 
(mg) 
Weight of sample 
(mg) 
Peak area of std 
Peak area of 
sample 
%Label claim 
LAM TDF LAM TDF LAM TDF LAM TDF 
1 
60 49 
208.80   4246.145 2065.267 99.16 100.01 
2 208.92 4281.874 2065.009 4302.386 2075.293 100.48 100.50 
3 208.86   4266.586 2062.138 99.64 99.86 
Mean 99.76 100.12 
S.D 0.669 0.334 
%RSD 0.007 0.003 
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Fig 3:  Typical HPLC Chromatogram corresponding to marketed formulation of LAM and TDF 
 
4. Conclusion 
    The proposed RP-HPLC method is simple, 
sensitive, reproducible, less time consuming and is 
applicable for analysis of Lamivudine and Tenofovir 
in bulk and in tablet dosage forms. The method was 
duly validated by evaluation of required parameters. 
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